Alpha Tau Medical (NASDAQ:DRTS) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) saw unusually-strong trading volume on Monday . Approximately 527,329 shares changed hands during mid-day trading, an increase of 8% from the previous session’s volume of 486,429 shares.The stock last traded at $10.04 and had previously closed at $10.83.

Wall Street Analyst Weigh In

A number of analysts have recently commented on DRTS shares. Piper Sandler boosted their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 19th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday. Citigroup boosted their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. LADENBURG THALM/SH SH boosted their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Finally, Zacks Research raised shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alpha Tau Medical currently has a consensus rating of “Hold” and a consensus price target of $12.20.

Alpha Tau Medical Price Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. The company’s 50-day simple moving average is $8.38 and its 200-day simple moving average is $6.83. The stock has a market capitalization of $806.61 million, a P/E ratio of -13.33 and a beta of 1.19.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). As a group, sell-side analysts expect that Alpha Tau Medical Ltd. will post -0.6 EPS for the current fiscal year.

Institutional Trading of Alpha Tau Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mariner LLC raised its position in Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after acquiring an additional 1,915 shares in the last quarter. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical during the fourth quarter worth $48,000. Levin Capital Strategies L.P. raised its position in Alpha Tau Medical by 6.3% during the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock worth $923,000 after acquiring an additional 12,200 shares in the last quarter. Envestnet Asset Management Inc. bought a new stake in Alpha Tau Medical during the third quarter worth $62,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. 2.65% of the stock is owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.